ExpreS2ion Biotech Holding AB (EXPRS2) - Total Liabilities
Based on the latest financial reports, ExpreS2ion Biotech Holding AB (EXPRS2) has total liabilities worth Skr29.42 Million SEK (≈ $3.17 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore ExpreS2ion Biotech Holding AB (EXPRS2) cash flow conversion to assess how effectively this company generates cash.
ExpreS2ion Biotech Holding AB - Total Liabilities Trend (2013–2025)
This chart illustrates how ExpreS2ion Biotech Holding AB's total liabilities have evolved over time, based on quarterly financial data. Check ExpreS2ion Biotech Holding AB asset resilience ratio to evaluate the company's liquid asset resilience ratio.
ExpreS2ion Biotech Holding AB Competitors by Total Liabilities
The table below lists competitors of ExpreS2ion Biotech Holding AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Michelmersh Brick Holdings Plc
LSE:MBH
|
UK | GBX36.10 Million |
|
Cyber Security 1 AB
ST:CYB1
|
Sweden | €23.14 Million |
|
Biodexa Pharmaceticals
NASDAQ:BDRX
|
USA | $3.39 Million |
|
Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG
XETRA:EFF
|
Germany | €18.41 Million |
|
CAT STRATEGIC MET.
F:8CHA
|
Germany | €1.53 Million |
|
Windtree Therapeutics Inc
NASDAQ:WINT
|
USA | $27.58 Million |
|
NewGenIvf Group Limited Class A Ordinary Shares
NASDAQ:NIVF
|
USA | $6.82 Million |
Liability Composition Analysis (2013–2025)
This chart breaks down ExpreS2ion Biotech Holding AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ExpreS2ion Biotech Holding AB market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.04 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.82 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.45 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ExpreS2ion Biotech Holding AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ExpreS2ion Biotech Holding AB (2013–2025)
The table below shows the annual total liabilities of ExpreS2ion Biotech Holding AB from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr29.42 Million ≈ $3.17 Million |
-26.65% |
| 2024-12-31 | Skr40.11 Million ≈ $4.32 Million |
+200.95% |
| 2023-12-31 | Skr13.33 Million ≈ $1.43 Million |
-60.84% |
| 2022-12-31 | Skr34.04 Million ≈ $3.66 Million |
+193.16% |
| 2021-12-31 | Skr11.61 Million ≈ $1.25 Million |
-52.24% |
| 2020-12-31 | Skr24.31 Million ≈ $2.62 Million |
+22.86% |
| 2019-12-31 | Skr19.79 Million ≈ $2.13 Million |
+56.37% |
| 2018-12-31 | Skr12.65 Million ≈ $1.36 Million |
+20.53% |
| 2017-12-31 | Skr10.50 Million ≈ $1.13 Million |
-10.54% |
| 2016-12-31 | Skr11.73 Million ≈ $1.26 Million |
+16.19% |
| 2015-12-31 | Skr10.10 Million ≈ $1.09 Million |
+222.22% |
| 2014-12-31 | Skr3.13 Million ≈ $337.34K |
+44.07% |
| 2013-12-31 | Skr2.18 Million ≈ $234.15K |
-- |
About ExpreS2ion Biotech Holding AB
ExpreS2ion Biotech Holding AB (publ), a biotechnology company, develops vaccines and biologics products to address critical unmet medical needs in the Nordics and internationally. The company's lead asset is ES2B-C001, a therapeutic vaccine which is in Phase 1 clinical trials for breast cancer that targets the human epidermal growth factor receptor 2. It is also developing ES2B-I002, a cytomegalo… Read more